SCHEMBL21495070

SCHEMBL21495070

COc1ccc(COC(=O)Nc2nc(-c3ccc(N4CCOCC4)nc3)cs2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 2/20 0.51
MAPT P10636 9/20 0.50
SMN1; SMN2 Q16637 8/20 0.50
ALDH1A1 P00352 7/20 0.50
LMNA P02545 6/20 0.50
HTT P42858 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPK1 P28482 6/20 0.49
GAA P10253 1/20 0.49
PTBP1 P26599 1/20 0.49
ACHE P22303 1/20 0.47
RAB9A P51151 8/20 0.46
NPC1 O15118 7/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ROCK1 Q13464 2/20 0.46
APP P05067 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21495080 0.88 MAPT (0.46) WNT3AMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL28518770 0.80 LMNA (0.50) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL21495067 0.78 MAPT (0.51) WNT3AMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL21505889 0.77 LMNA (0.46) WNT3AMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL21495029 0.75 MAPT (0.59) WNT3AMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL24170725 0.74 MAPT (0.47) WNT3AMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL9376371 0.74 LMNA (0.78) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL21484611 0.73 WNT3A (0.48) WNT3AMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL18425338 0.71 ACHE (0.66) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL3311430 0.70 LMNA (0.60) MAPTSMN1; SMN2ALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 WNT3A 3841/4885MAPT 706/4885SMN1; SMN2 104/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 WNT3A 3841/4885MAPT 706/4885SMN1; SMN2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.